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The X-linked form of spondyloepiphyseal dysplasia tarda (SEDL), a radiologically distinct skeletal dysplasia affecting
the vertebrae and epiphyses, is caused by mutations in the SEDL gene. To characterize the molecular basis for
SEDL, we have identified the spectrum of SEDLmutations in 30 of 36 unrelated cases of X-linked SEDL ascertained
from different ethnic populations. Twenty-one different disease-associated mutations now have been identified
throughout the SEDL gene. These include nonsense mutations in exons 4 and 5, missense mutations in exons 4
and 6, small (2–7 bp) and large (11 kb) deletions, insertions, and putative splicing errors, with one splicing error
due to a complex deletion/insertion mutation. Eight different frameshift mutations lead to a premature termination
of translation and account for 143% (13/30) of SEDL cases, with half of these (7/13) being due to dinucleotide
deletions. Altogether, deletions account for 57% (17/30) of all known SEDL mutations. Four recurrent mutations
(IVS3+5GrA, 157–158delAT, 191–192delTG, and 271–275delCAAGA) account for 43% (13/30) of confirmed
SEDL cases. The results of haplotype analyses and the diverse ethnic origins of patients support recurrentmutations.
Two patients with large deletions of SEDL exons were found, one with childhood onset of painful complications,
the other relatively free of additional symptoms. However, we could not establish a clear genotype/phenotype
correlation and therefore conclude that the complete unaltered SEDL-gene product is essential for normal bone
growth. Molecular diagnosis can now be offered for presymptomatic testing of this disorder. Appropriate lifestyle
decisions and, eventually, perhaps, specific SEDL therapies may ameliorate the prognosis of premature osteoarthritis
and the need for hip arthroplasty.
Introduction
Spondyloepiphyseal dysplasia tarda (SEDT) is a genet-
ically heterogeneous disorder of vertebral and epiphyseal
growth, commonly culminating in degenerative osteoar-
thropathy of the hip joint (Byers et al. 1978; Kaibara et
al. 1983; Beighton 1997). The main clinical features of
this progressive skeletal disorder are disproportionately
short-trunked short stature due to platyspondyly, and
dysplasia of the large joints, frequently necessitating hip
replacements in the third decade of life. It is the pattern
of inheritance and the characteristic radiological ap-
pearance of the vertebrae that delineate the X-linked
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form (SEDL [MIM 313400]) from those with autosomal
modes of inheritance (MIM 271600 and MIM 184100).
The mean adult height in affected males, for all forms
of SEDT, is !150 cm (Wynne-Davies et al. 1985), al-
though SEDL results in a more pronounced short-trunk
condition than do the autosomal forms (Iceton and
Horne 1986).
The distinctive radiological signs in males affected
with the X-linked form are the hump-shaped central
and posterior portions of characteristically flattened
thoracic and lumbar vertebral bodies (Bannerman et al.
1971; Harper et al. 1973). Although the initial presen-
tation usually occurs in late childhood (age 5–10 years),
with vague back pain and a decline in growth velocity,
the skeleton is radiologically normal up to the age of 5
years (Heuertz et al. 1993; MacKenzie et al. 1996), and
the diagnosis may not be made until early adulthood.
Expression of the disorder can vary from relative free-
dom from musculoskeletal complaints to limited spine
mobility and premature osteoarthritis of the major
proximal weight-bearing joints (Iceton and Horne
Gedeon et al.: Mutational Spectrum of the SEDL Gene 1387
1986; Whyte et al. 1999). Limb lengths (usually ex-
pressed as arm spans) do not appear to be involved.
The upper torso of an affected male, however, is com-
monly described as “barrel chested,” as a result of the
shortened spine and consequently elevated ribs (Mac-
Kenzie et al. 1996; Whyte et al. 1999).
Over a 30-year period in Britain, 19% of skeletal
dysplasia index cases in patients requiring orthopedic
care were classified as SEDT, with 22% of these re-
corded as being the X-linked recessive form (Wynne-
Davies and Gormley 1985). The estimated prevalence
figure of 1.7/1,000,000 (Wynne-Davies and Gormley
1985) is, however, likely to be an underestimate, since
it represents only those symptomatic patients who pre-
sented for treatment and in whom X-linked family his-
tory was documented or inferred. In the absence of clear
radiographic evidence, it may also be that, in the past,
atypical or isolated SEDL cases were classified as being
autosomal SEDT. The true prevalence of X-linked SEDL
has yet to be determined.
We recently identified the SEDL gene in Xp22 (MIM
300202), consisting of six exons and encoding a protein
of 140 amino acids with a putative role in vesicular
transport (Gedeon et al. 1999). We have subsequently
shown that recombinant human and mouse SEDL pro-
teins localize to perinuclear structures consistent with
the functional location of the yeast ortholog (Gecz et
al. 2000). Initial screening of the SEDL gene in three
Australian families with SEDL identified three different
dinucleotide deletions that effected frameshifts of the
open reading frame (ORF) (Gedeon et al. 1999). The
purpose of the present study was to determine the spec-
trum of novel mutations in the SEDL gene in 36 un-
related patients with clinically diagnosed SEDL. By
characterizing additional SEDL mutations, we aimed to
determine essential functional domains necessary for
normal bone growth and skeletal development and to
examine phenotype/genotype correlation. We report 21
pathogenic SEDL mutations accounting for the SEDL
phenotype in 30 patients.
Subjects, Material, and Methods
Patients with SEDL
A total of 36 unrelated patients were analyzed for this
study. Genomic DNA from 33 new index patients with
SEDL from various populations were screened for mu-
tations in the SEDL gene. The contributing clinician in
each case established the diagnosis of SEDL, by clinical
and radiological means, and obtained informed consent.
All males in this study had disproportionately short-
trunked short stature. In most cases, the diagnosis in-
cluded radiography of the lumbar vertebrae and epiph-
yses, to visualize the characteristic humping of the centra
of the vertebral bodies. The source and ethnic origin of
the 30 patients confirmed to have X-linked SEDL are
presented in table 1, including those from three Austra-
lian families described elsewhere (Gedeon et al. 1999).
Of the 27 new patients with SEDL in this study, 17 came
from families in which X-linked inheritance was clear
or strongly suspected on the basis of anamnestic evi-
dence, with no male-to-male transmission of the phe-
notype. Several of these families have been characterized
previously, and the disorder either was shown to seg-
regate with or could not be excluded from the linked
DXS16–DXS987 SEDL genetic interval (Heuertz et al.
1995; Bernard et al. 1996; Gedeon et al. 1999; Tiller et
al. 2001 [in this issue]).
Clinical summaries were not available for all patients
in the present report. In all subjects for whom anthro-
pometric measurements were available, the upper-to-
lower body-segment ratio (U:L) was !1.0, and arm spans
exceeded adult heights (table 2). Clinical data on four
new Australian patients—patients 2, 26, 28, and 30—as
well as on patient 6 (proband III-1 in family 1 of Bernard
et al. [1996]) are summarized in table 2, along with the
three previously described Australian patients (Gedeon
et al. 1999), referred to here as patients 3, 10, and 13.
Mutation Detection
In each patient, each of the four exons comprising the
SEDL ORF, as well as their exon/intron boundaries,
were analyzed by direct sequencing of PCR products,
through use of flanking intronic primers (Gedeon et al.
1999). PCR conditions were 35 cycles of 30 s each of
94C, 58C, and 72C. The PCR-amplification product
was purified by QIAquick centrifugation according to
the manufacturer’s (QIAGEN) instructions. A 100-ng
aliquot of the purified sample was cycle sequenced with
the ABI prism BigDye Terminator Cycle Sequencing
Ready Reaction kit (Perkin-Elmer Applied Biosystems),
in the presence of equal-part halfBD (Genpak). The
sequencing primers were the same as those used for tem-
plate amplification (Gedeon et al. 1999). An X-specific
reverse primer, 3XR (CAT ATT ATA CCA TAT CAT
TAC AAT AGC), was used for amplification or sequenc-
ing in those male samples in which the exon 3 primers
amplify the Y copy. The sequencing reactions were elec-
trophoresed on ABI automated sequencers, and the re-
sultant chromatograms were analyzed by Lasergene soft-
ware (DNA Star) and compared against normal se-
quences (GenBank).
Mutations (fig.1) are numbered from 1, beginning at
the first nucleotide of the translation start (den Dunnen
and Antonarakis 2000). For each mutation identified in
a subject, segregation with the affected phenotype was
confirmed either in family members, when available, or
by screening of 50 control chromosomes, to exclude
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Figure 1 Schematic representation of the spectrum of mutations of the SEDL gene. Solid boxes represent the SEDL ORF, hatched boxes
represent the UTR of the gene. Twenty-one different mutations of all types were found to have pathogenic consequences in 30 unrelated SEDL
cases. Asterisks (*) indicate recurrent mutation events.
polymorphisms and rare variants. Additional family
members were available for patients 1, 3–6, 8–11, 13,
14, 18–22, and 27 (table 1). Segregation of the mutation
with the disorder was demonstrated as follows: by re-
striction-endonuclease digestion of the PCR product, fol-
lowed by visualization on 1.5% agarose gels (when an
enzyme site was created or destroyed); on 5% polyacryl-
amide gels (for small deletions); by single-stranded con-
formation analysis (SSCA) on either MDE (FMC Cor-
poration) or 10% nondenaturing polyacrylamide gels; or
by direct sequencing. To determine the extent of gross
deletion of exon 3 in patient 2 and exon 6 in patient 30,
extra primers were designed in exon 2 (SEDLE2F [CCC
AAG TGT GAC AAC CAA AGA TG] and 1BR [CTT
TAC CTC ACA GCA CAC AAT GG], amplicon 129 bp)
and flanking exon 6 (6AF [GTG GTC TTT AGA CTT
TGG AAT GTC] and 6BR [CAA CAG AGT GAG ACT
CTG TAT CA], amplicon 504 bp).
RT-PCR
When available, RNA was extracted from peripheral
blood lymphocytes, to examine the effect of SEDL mu-
tations on SEDL-gene transcription and processing. RT-
PCR experiments were performed on total RNA, as de-
scribed elsewhere (Gecz et al. 2000).
To examine the consequence of the complex intron 5
deletion/insertion mutation in patient 27, RT-PCR was
performed using either primers E1F2 (CTT CCG CGG
AAA CTG ACA TTG C) and E4R1 (ATG CCC CGC
AGT GAC AAA TGC C), from the 5′ end of the SEDL
gene (fig. 2a), or primers SEDLF1 (GGC CAC CAT GAT
AAT CCA GT) and SEDL5RX (GTA TAC ACC ATT GTG
GTG ACA TC), flanking the exon 5/exon 6 splice site
(fig. 2b).
To examine the SEDL RNA of the exon 3 deletion in
patient 2, primers from exon 1 (E1F2) and exon 6
(SEDL5Rx) were used. By these primers, which span the
alternatively spliced exon 2 of SEDL, two RT-PCR prod-
ucts, of 679 bp and 537 bp, are amplified only from the
X-linked SEDL gene; in the absence of exon 3 (as in
patient 2), 567-bp and 425-bp products are generated
instead (fig. 2c).
Haplotype Analysis
Disease-associated haplotypes were constructed by
the genotyping of seven polymorphic loci flanking
SEDL (DXS7109, DXS1224, DXS16, AFMa124wc1,
DXS8022, AFM126ye11, and DXS987). The genetic dis-
tance covers 7 cM between DXS7109-2.6 cM-DXS1224-
3.1 cM-DXS8022-1.3 cM-DXS987 (Nagaraja et al.
1997), with the SEDL gene mapped to the 170-kb interval
between markers DXS16 and AFMa124wc1 (Gedeon et
al. 1999). To determine whether recurrent mutations were
due to identity by descent (IBD) from a founder mutation,
the haplotypes of unrelated samples were compared. Hap-
lotypes were also generated from two female CEPH con-
trols representing four normal X chromosomes.
Results
Mutation Analysis in Patients with SEDL
In 27 new index patients, mutations were found that,
together with three previously described dinucleotide de-
letions, account for the SEDL phenotype in 30 affected
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Figure 2 RT-PCR analysis of the SEDL gene in patient 27 (insertion/deletion of intron 5) and patient 2 (deletion of exon 3). Total RNA
from blood lymphocytes was reverse transcribed with Superscript II reverse transcriptase (see Subjects, Material, and Methods section) and was
PCR amplified with SEDL primers. Schematic diagrams indicate the positions of the RT-PCR primers used, the SEDL mutations tested, and
the occurrence of the alternative splicing of exon 2. “gDNA” denotes normal genomic DNA used as a control; plus () and minus () signs
denote presence and absence, respectively, of reverse transcriptase during the reverse transcription step of the RT-PCR; the asterisk (*) denotes
presence of heteroduplexes; and pUC/HpaII and SPPI/EcoRI are molecular-weight markers. A, Primers spanning SEDL exons 1–4. These primers
amplify a 451-bp SEDL-gene product, when exon 2 is spliced in, or a 309-bp product, when exon 2 is spliced out. These two primers also
amplify genomic DNA of the chromosome 19 (SEDLP1) pseudogene (309-bp product). This product was present in lymphocyte RNA from
patient 27. B, Primers spanning exons 3–6 of SEDL. When these primers were used, no SEDL PCR product was amplified from patient 27’s
lymphocyte RNA, indicating alternative 3′ processing of the SEDL RNA, as a consequence of the insertion/deletion mutation. Esterase D (ESD)
RT-PCR is used as a control of RNA quality. C, RT-PCR amplification using primers spanning exons 1–6 from patient 2’s lymphocyte RNA.
This patient carries a deletion of exon 3. Exon 3 is missing from its spliced SEDL transcript, demonstrated as a shift of 112 bp (exon 3 size)
of both SEDL exon 2 and exon 2 isoforms.
individuals (table 1). Four mutations occurred in more
than one unrelated family or individual and affect 43%
(13/30) of patients with confirmed cases of SEDL. A total
of 21 different pathogenic SEDL gene–sequence alter-
ations have now been identified that affect the SEDL
ORF (fig. 1). None of these changes were present in
control chromosomes. Six patients in the present study
had no detectable mutation in the SEDL ORF or in the
sequences adjacent to each exon/intron boundary. Al-
though noncoding mutations affecting regulation of
SEDL cannot be excluded, these patients may not have
X-linked SEDL.
Eight single-base substitutions were found, three of
which caused missense amino acid substitution and two
of which resulted in nonsense mutations; of the remain-
ing three, two occurred at splice-acceptor sites, and only
one occurred at a splice-donor site. Except for the latter,
each point mutation occurred only once in this cohort
of patients with SEDL. Deletion mutations were the most
common pathogenic mutation affecting the SEDL gene,
accounting for 17 (56%) of the 30 cases. Although re-
currence of three deletions was observed, 12 (57%) of
the 21 different mutations disrupting SEDL are deletions
of two or more bases. Five dinucleotide and two pen-
tanucleotide deletions of the coding sequence affect
frameshift in the ORF of the gene and lead to premature
termination of translation, whereas three intronic dele-
tions are likely to disrupt splicing. RNA was available,
from patient 27, to assess the consequence of a complex
deletion/insertion in intron 5. RT-PCR showed normal
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Figure 3 Sequence chromatograms of two common mutations. Restriction digestion of exon 3 and exon 4 PCR products with TaiI detects
half of the recurrent mutations, accounting for 156% of all SEDL cases. A, IVS35GrA mutation, which abolishes a TaiI site (underlined) so
that the 265-bp exon 3 PCR product is resistant to cleavage into 197-bp and 68-bp fragments. B, 157–158delAT mutation in exon 4, which
creates a TaiI site cleaving the 289-bp product into 103-bp and 184-bp fragments. Carriers can be identified. A p affected, C p carriers, and
N p normal control.
transcription of exons 1–4 but no transcript with prim-
ers spanning exons 3–6 (fig. 2), indicating alternative 3′
processing due to a lack of splicing of exon 6.
Larger deletions were suggested in two patients by the
lack of PCR amplification products. In one of these,
patient 2, the gene was deleted for exon 3 but was not
found to be deleted when tested with primers (SEDLE2F
and 1BR) within SEDL exon 2, limiting the deletion to
exon 3, which contains the ATG start site (results not
shown). Southern blot hybridization of an EcoRI digest
revealed deletion of exon 3, with no evidence of a junc-
tion fragment, implying complete deletion of this exon
(data not shown). RT-PCR experiments on lymphocyte
RNA of patient 2 with SEDL exon 1–specific (E1F2)
and exon 6–specific (SEDL5RX) primers confirmed com-
plete absence of exon 3 from the processed SEDL tran-
script (fig. 2c). In the other patient, patient 30, the de-
letion of exon 6 involves the entire 504-bp 6AF-6BR
PCR product but does not extend to the polymorphic
marker DXS16 distal to SEDL. To more precisely char-
acterize this deletion and, particularly, to investigate
whether this deletion extends beyond the SEDL gene,
long-range PCR across exons 5 and 6 was performed.
A junction fragment showing a deletion of ∼1.3 kb was
amplified from the patient’s DNA and sequenced. Se-
quence analysis revealed that in this subject, patient 30,
1,330 bp of gDNA was deleted. This deletion occurred
between two Alu sequences, one lying within intron 5
and the other being the first Alu sequence of exon 6 of
the SEDL gene (results not shown). We speculate that
the most likely cause of this deletion was an intrachro-
mosomal Alu-Alu sequence–mediated recombination
with subsequent deletion of the inter-Alu sequences.
The mutations of the splice-donor site in intron 3
(IVS35GrA) and the deletion of five consecutive bases
in exon 5 (271–275delCAAGA) are the most common
(table 1). The recurrent GrA transition in the intron 3
splice donor abolishes a TaiI restriction site. The iso-
schizomer of MaeII, TaiI, is useful as a diagnostic tool
for screening for the recurrent splice mutation of exon
3, as well as for the 157–158delAT deletion in exon 4
(fig. 3). In families with the recurrent IVS35GrA
splice-donor mutation, the TaiI site is destroyed in intron
3, and TaiI digestion of the 265-bp PCR products will
cut only normal sequences. In patient 10, as in patient
11, a TaiI site is created by the deletion of the nucleotides
AT at positions 157 and 158 in exon 4 and could be
used to confirm segregation of the mutation with the
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Table 3
Genotypes at Seven Polymorphic Loci Flanking the SEDL Locus
MUTATION AND
PATIENT DNA NUMBERa
GENOTYPE AT
DXS7109 DXS1224 DXS16 (SEDL)b AFMa124wc1 DXS8022 AFM126ye11 DXS987
Controls:
1347-02 139 159 3,4 3 176, 178 A, B 206, 216
1331-02 141 159, 167 2 2 160, 178 A, B …
IVS35GrA:
SED1 139 159 4 3 172 A 220
10008 139 159 4 1 176 A …
10191 139 165 5 3 160 B …
157–158delAT:
6513 139 159 5 1 180 B 206
SED6 139 159 5 … 178 B 206
191–192delTG:
4937 141 167 9 3 168 B 206
SED7 139 165 4 2 178 A 216
271–275delCAAGA:
SED3 139 159 6 1 168 A 216
10010 141 159 5 3 176 A …
a Haplotypes can be compared between individuals with the same SEDL mutation and against those of normal female CEPH controls.
b (SEDL) is shown for the purpose of location only.
phenotype in the family and for subsequent carrier de-
tection. Cosegregation of the disorder with other dele-
tion mutations was confirmed, in each of the remaining
families, by fragment-size variation of PCR products on
5% polyacrylamide gels or by SSCA analysis (results not
shown).
Haplotype Analysis
Haplotypes around the SEDL gene were used to de-
termine whether recurrent mutations of the SEDL gene
could be due to ancestral mutation events. Haplotype
analysis in at least one pair of patients with each re-
current mutation gave no evidence to support IBD (table
3). Many patients have diverse ethnic origins (table 1),
although those with the recurrent splice-donor mutation
in intron 3 are all of European origin. The 5-bp deletion
in exon 5 occurs in people of differing ethnicity. Two of
the dinucleotide deletions described in the first three Aus-
tralian families reported (Gedeon et al. 1999) were also
detected in two French families. Those sharing the
191–192delTG mutation have entirely different haplo-
types around the SEDL gene, rendering a founder an-
cestor highly unlikely.
Correlation of Genotype with Phenotype
Objective assessment of the severity of the SEDL phe-
notype is difficult, since intrafamilial variation is not
unusual; however, there does appear to be a trend of
decreasing severity, within the group of patients de-
scribed, in the order of their mutations, 5′r3′, along the
gene (table 2). The severity of the condition in patient
2, compared with that in patient 28 or in asymptomatic
patient 30, is suggestive of some genotype/phenotype
correlation. It appears that mutations affecting exons 5
and 6 in this subset of patients result in a milder clinical
condition, with little or no hip pain and no evidence of
kyphosis or scoliosis. Toward the 5′ end of SEDL, mu-
tations in exons 3 and 4 result in kyphosis and scoliosis,
with both severe pain evident earlier in life and a more
debilitating set of complications. Although no obvious
correlation with phenotype was apparent, that may be
a reflection of the ascertainment bias for patients in-
cluded in the present study; on the other hand, patient
22 carries the pentanucleotide deletion in exon 5 and is
one of three brothers, described by Iceton and Horne
(1986), who have had different clinical courses, from a
lack of symptoms to disabling arthritis.
Of the six patients with no identified SEDL mutation,
three had no family history of the disease. One of these
had hip pain provoked by exercise, and degenerative
changes and characteristic platyspondyly of the spine.
Given the absence of an identifiable SEDL mutation, an
alternative diagnosis, of mild Kniest syndrome with no
eye or hearing problems, is possible. In the three others
clinically assessed as having SEDL, two had unknown
family history and one was a member of a sibship of
three affected males in whom, although x-rays were not
wholly typical, the clinical diagnosis had never been
doubted.
Discussion
In our initial study of SEDL, three Australian families
carried truncating mutations (Gedeon et al. 1999). The
present study describes the 21 novel mutations account-
1394 Am. J. Hum. Genet. 68:1386–1397, 2001
ing for the X-linked SEDL phenotype in 30 of 36 in-
dependently ascertained patients. These mutations,
which are spread throughout the gene, include point
mutations, splice alterations, an insertion, several dele-
tions, and a complex deletion/insertion. Four mutations
were found more than once in this cohort of patients,
indicating clustering at more-mutable sites within the
gene. None of the familial mutations could be traced
back to their origins. In those isolated cases in which
the patient’s mother was available for testing, she was
confirmed to be a carrier.
The most common type of SEDL-gene disruption was
deletion, representing 40% of the types of detected
SEDL mutations. Several different deletions of 2–5 bp
and two large deletions within the coding sequence
caused frameshifts and accounted for 14/30 (46%) of
SEDL cases. Three deletions within introns affected nor-
mal splicing and resulted in the removal of large por-
tions of coding sequence. Three of four identified re-
current mutations were deletions. More than half of all
confirmed SEDL cases were due to a deletion, with al-
most one quarter due specifically to dinucleotide dele-
tions. This number is up to 10-fold greater than the
average deletion frequency (5%–10%) in disease-caus-
ing genes (Wicking and Williamson 1991) and ap-
proaches that quoted for Duchenne muscular dystrophy
(Koenig et al. 1987; Forrest et al. 1988). This is an
unusually high deletion frequency, particularly in a gene
encoding only a small protein of 140 amino acids. The
five copies of SEDL mapped to the Y chromosome
(Gecz et al. 2000) may provide a possible mechanism
to explain the high frequency of deletion mutations af-
fecting this gene through homologous recombination
and slipped mispairing.
Nucleotide-base substitutions were a relatively less
common type of mutation contributing to the patho-
genesis of SEDL. Equal numbers of transitions and
transversions were present. All five nonsynonymous
base substitutions, however, alter the amino acids that
are highly conserved across species. D47 and L61 are
the most highly conserved across mouse, rat, fruit fly,
yeast, and worm, whereas S73, Q91, and V130 are
retained in the mouse and rat (Gedeon et al. 1999). The
SEDL-gene function is not clear, but knowledge of the
role of the yeast ortholog in endoplasmic reticulum-to-
Golgi transport, and the subcellular localization of nor-
mal sedlin constructs, supports the possibility that the
SEDL protein may be involved in intracellular trans-
portation of molecules (Gecz et al. 2000).
In the present study, we observed eight small deletion/
insertion mutations of the ORF that cause frameshifts
in a maximum of 13 independent events over a target
sequence of only 420 bp. By comparison, Gianelli et al.
(1999) observed 17 independent events of such types of
mutation in the 1,362-bp factor IX–coding sequence.
The uncommonly high frequency of deletion mutations
in SEDL would explain this disparity. All eight muta-
tions result in a shift to the same alternate SEDL reading
frame that accordingly terminates in one of three new
downstream stop positions, at D87X, T100X, or
E116X. The most 3′ of these arises because of the
320–321insT mutation, which causes silent changes at
amino acids 107 and 108, maintaining the Ile(I) and
Lys(K) sequences—with the first putative protein vari-
ation introduced by the frameshift, not detectable until
F109V, culminating in E116X. At the protein level,
there may be some functional dependency on the highly
conserved amino acids 111–115. This amino acid se-
quence, MNPFY, is conserved in mouse, rat, worm, and
yeast, with the NPFY being retained also in fruit fly
(Gedeon et al. 1999). Of course, the early truncation of
the protein will also affect the putative Golgi-targeting
domains within the COOH terminus. Subcellular-lo-
calization studies of constructs of a naturally occur-
ring nonsense mutation in exon 5 (C271T) and of
157–158delAT showed misplacement of the protein
from the vesicular tubular complex VTC/Golgi to the
cell nucleus (Gecz et al. 2000). On the basis of this
finding, it can be predicted that the remaining mutations
that lead to a polypeptide truncated at D87X—for ex-
ample, 191–192delTG and 241–242delAT—would also
show a loss of function of the protein, through mis-
placement of the SEDL protein within the cell.
One-third of the SEDL cases are due to mutations
that result in a putative splicing error. The recurrence
of one of these in particular—IVS35GrA, affecting
splicing of exon 3—is a transitional base substitution
in the consensus splice donor. This changes the consen-
sus strength from 84% to 5% at this nucleotide (Shapiro
and Senepathy 1987). Experimental demonstration of
this splicing error and of its effects on tissue histology
will be discussed in detail elsewhere (Tiller et al. 2001
[in this issue]). Ethnic and haplotype differences support
the recurrence of this disease-causing mutation (tables
1 and 3). The splice-acceptor–site mutations in introns
2 and 5 of SEDL may cause skipping of following exons
(and of the initiator methionine in patient 1), retention
of the intron in the final mRNA, or activation of a
cryptic splice site, all potentially causing changes to the
protein (Maquat 1996). The deletions in donor splice
sites in intron 4 (i.e., 2419 through 12 and 2414
through 11) may have the same effects on the con-
sensus splice site or may alter a branch site, affecting
recognition of the splice junction by the spliceosome.
Since only genomic DNA was available in most cases,
the consequences of these splice-site mutations could
not be proved experimentally.
Haplotype analyses in patients sharing each of the
four common mutations demonstrated that the SEDL
gene is subject to recurrent mutation rather than to an
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ancestral founder mutation (table 3). The 157–
158delAT haplotypes are the same at several flanking
loci but are also the same as one of the control hap-
lotypes. The various ethnic origins of four patients with
the CAAGA pentanucleotide deletion in exon 5 also
indicate recurrence rather than IBD of this mutation. A
similar 5-bp deletion mutation has also been detected
in a large family with SEDL from Arkansas (Mumm et
al. 2000). The sequence in this region is such that the
5-bp deletion could be any one of five alternatives (AA-
GAC, AGACA, GACAA, ACAAG, or CAAGA) that
include the C base at position 271. Two other muta-
tions—C271T and 272–273delAA—also disrupt the
glutamine amino acid at position 91. One might spec-
ulate that the sequence in this region is relatively more
vulnerable to pathogenic mutation than is the remainder
of the gene.
Given the spectrum of mutations altering the expres-
sion of the SEDL gene, the phenotypic findings in these
families with SEDL have shown a remarkable degree of
homogeneity. The large-scale deletions involving exons
at either end of the gene do not seem to have more-
deleterious consequences; however, the additional fea-
tures of kyphosis and scoliosis and the reporting of pain
appear to be greater and to occur at an earlier age when
mutations are at the 5′ end of the ORF. On the other
hand, in terms of relative severity, tolerance of exercise
in two other Australian patients has been unimpeded
by the condition. It appears that, among affected fam-
ilies, there is no clearly distinguishable clinical effect of
the types of mutation, including missense and trunca-
tion mutations, despite the considerable allelic hetero-
geneity of SEDL. There do not seem to be any specific
regions of functional significance in the SEDL gene that
have a role in determining the severity of the primary
clinical outcome. There is insufficient clinical variation
to predict the phenotype based on the genotype, though
this may reflect the ascertainment, for inclusion in the
study, of patients with a specific phenotype commonly
accepted as typical SEDL.
The SEDL phenotype might be explained by reduced
endochondral bone growth at the epiphyses, particu-
larly in the vertebral bodies. The autosomal forms of
SEDT can largely be accounted for by mutations in the
type II procollagen gene (COL2A1), which suggests
some functional interaction between sedlin and colla-
gen. Recurrent R519C mutations in COL2A1 are
known to be associated with mild, late-onset spondy-
loepiphyseal dysplasia (SED) and precocious general-
ized osteoarthritis (Ala-Kokko et al. 1990; Holderbaum
et al. 1993; Williams et al. 1995; Bleasel et al. 1998).
A spectrum of COL2A1 mutations cause more-severe
disorders of long-bone growth, through alteration of
the assembly, interactions, and secretion of the collagen
triple helix (Kuivaniemi et al. 1997). The R519C mu-
tation may alter this “end molecule,” such that an in-
teracting surface is not exposed, or in a way that would
slow secretion of the molecule (Byers 2000). Similarly,
the SEDL mutations may prevent SEDL-protein inter-
actions with other proteins in the TRAPP complex
(Gecz et al. 2000), which may itself have a role in col-
lagen biosynthesis and/or transport.
Currently the diagnostic precision of “X-linked”
SEDL, in the absence of clear radiographic features,
rests on recognition of the mode of inheritance. Of six
additional patients, who, on the basis of clinical de-
scriptions, were tested for SEDL mutation, three had
no family history and three had unknown family history
beyond that of the nuclear family. Some had flattened
vertebral bodies shown on radiographic examination,
but none had a detectable mutation in the analyzed ORF
or in the closely flanking intronic sequences. These pa-
tients may have mutations in regions of the gene that
were not tested, such as in introns away from the exon-
intron boundaries or in regulatory elements, or they
may be autosomal phenocopies of SEDL. This suggests
that not all cases of SEDL are clinically recognizable.
Reexamination of the clinical data and mutation anal-
ysis of COL2A1 might be instructive for these patients.
The correct establishment of etiology and mode of in-
heritance is critical for determining the recurrence risks
and risks to relatives. Molecular analysis of SEDL will
now be a useful adjunct to clinical diagnosis and mo-
lecular analysis of COL2A1, to distinguish between the
X-linked and autosomal forms, particularly in sporadic
and atypical cases. The question of clinical heteroge-
neity caused by the SEDL gene remains, since the sam-
ple cohort included only those patients recognized clin-
ically as having typical X-linked SEDL. Although
heterogeneity may be sought where none exists, studies
to determine the role of SEDL in premature osteoar-
thritis are in progress. Only one study has been pub-
lished of a family with a severe X-linked variant of
spondyloepimetaphyseal dysplasia (SEMD) with dis-
tinctive phenotype and severe, progressive mental re-
tardation (Bieganski et al. 1999). Another family has
been described with nonsyndromic X-linked SEMD that
is clinically distinct from X-linked SEDL (Camera et al.
1994). SEMD may be part of the clinical picture defined
by the SEDL gene, or these families may represent the
heretofore-unrecognized genetic heterogeneity of X-
linked SED. The analysis of atypical cases will permit
estimation of the true prevalence of SEDL-gene muta-
tions and will give greater insight into the function of
the gene in bone growth.
That both the SEDL and adjacent Cxorf5 genes es-
cape X inactivation has been demonstrated in a first-
generation study of X inactivation (Carrel et al. 1999).
Recent microarray-expression profiling has confirmed
that SEDL and the nearby GPM6B also escape X in-
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activation (Sudbrak et al. 2001). These genes lie within
an ∼100-kb interval in Xp22 (Gecz et al. 2000). Such
a nonrandom distribution may indicate another mul-
tigene cluster escaping inactivation, similar to that de-
scribed in Xp11.2 (Miller and Willard 1998). The lack
of clear evidence of the SEDL phenotype in carrier fe-
males suggests that expression of the normal gene prod-
uct can compensate for expression of the defective gene.
The classic description of SEDL suggests that bone
growth and formation are normal in affected males dur-
ing infancy and early childhood. Longitudinal studies
of phenotype development may reveal a postnatal win-
dow of time during which therapeutic intervention may
reduce or override the ill effects of mutations. The timely
switching to up-regulate the endogenous expressed
pseudogene on chromosome 19 (Gedeon et al. 1999)
may provide a molecular means of therapy.
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